Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens

Next Previous
X
Search
Trial Profile

Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iclaprim (Primary) ; Vancomycin
  • Indications Gram-positive infections; Nosocomial pneumonia; Ventilator associated pneumonia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Arpida

    • Most Recent Events

    • 11 Jun 2018 Status changed to completed, according to a Motif Bio media release.
    • 26 Jul 2017 Primary endpoint (Efficacy: Clinical cure rate - comparison of the two iclaprim dosing regimens versus vancomycin) has not been met, as per results published in the Clinical Therapeutics.
    • 26 Jul 2017 Results published in the Clinical Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top